anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain an agent for a γ-interferon-susceptible disease useful for the prophylaxis and treatment of a virus disease, a malignant tumor, an immunological disease, etc., by compounding a human-derived γ-interferon. SOLUTION: This agent contains a γ-interferon produced by human-derived marrow monocyte cells proliferated from an established cell line as an active component. The γ-interferon is a protein having a specific activity of at least about 1.5×10<7> unit/mg-protein, and the agent usually contains the interferon about 1-10,000,000 unit per gram. The marrow monocyte cells are produced by transplanting some marrow monocyte cells of the established cell line into the body of a warm-blooded animal other than a human or into a diffusion chamber placed in or out of the body of a warm-blood animal other than a human and proliferating the cells under the supply of body fluid of the warm blood animal, or by proliferating according to tissue culture, etc., in which the marrow cells are transplanted into a nutritional medium.  Originally, γ-interferon was difficult to produce on an industrial scale since the productivity was poor. However, an established cell line of a human-derived marrow monocyte has extremely high productivity of γ-interferon.
The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
For current information on the management of olanzapine and fluoxetine overdose, consider contacting a Certified Poison Control Center (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. In managing overdose, consider the possibility of multiple drug involvement. Establish and maintain an airway and ensure adequate ventilation. Commence cardiovascular monitoring immediately and include continuous electrocardiographic monitoring to detect possible arrhythmias.

A specific precaution involves patients who are taking or have recently taken olanzapine and fluoxetine and may have ingested excessive quantities of a TCA (tricyclic antidepressant). In such cases, accumulation of the parent TCA and/or an active metabolite increases the possibility of serious sequelae and extends the time needed for close medical observation. 

Due to the large volume of distribution of olanzapine and fluoxetine, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidote for either fluoxetine or olanzapine overdose is known
The present application discloses a type of pyrimidine derivatives having small molecule, preparation methods and uses thereof. The present pyrimidine derivatives are described as formula (I). The present application uses chromones as the original material. The chromones are halogenated to be one of the component of polycomponenet reaction. The halogenations are coupled with various aryl- or heteroaryl boronic acids, or thioaza-heterocyclic compounds, then condensed with amidines to obtain the present compounds. These compounds have antivirus or antitumor activities. After optimizing or screening from these compounds, we can obtain new drugs which can be used to prevent virus or tumor.
RATIONALE: Increasing evidence shows that imidazoline I2 receptor agonists enhance opioid-induced analgesia, suggesting that the combination of I2 receptor agonists with opioids could be a favorable strategy for pain control. However, the effect of I2 receptor agonists on the abuse liability of opioids is unknown. This study examined the impact of the I2 receptor agonist 2-BFI on some abuse-related behavioral effects of the opioid morphine in rats.
OBJECTIVES: The von Frey filament test was used to determine the antinociceptive effects of 2-BFI (intravenous, i.v.) in a rat model of complete Freund's adjuvant (CFA)-induced inflammatory pain. IV self-administration was used to assess the reinforcing effects of 2-BFI alone and to assess the effects of non-contingent injections of 2-BFI (i.p.) on morphine self-administration. A two-lever drug discrimination paradigm in which rats were trained to discriminate 3.2 mg/kg morphine (i.p.) from saline was used to examine whether 2-BFI or another I2 receptor agonist 2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride (BU224) affected the discriminative stimulus effects of morphine.
RESULTS: 2-BFI could not maintain reliable self-administration behavior in rats with no pain or CFA-treated inflammatory pain. However, pretreatment with 2-BFI (i.p.) produced dose-dependent decreases in the dose-effect curve of morphine self-administration. Both 2-BFI and BU224 did not substitute for morphine but significantly attenuated the discriminative stimulus effects of morphine.
CONCLUSIONS: These results suggest that I2 receptor agonists do not enhance, but in fact appear to decrease, the abuse liability of opioids, further supporting the potential utility of I2 receptor agonist-opioid combination therapy for pain control.
I ABSTRACT The invention relates: A. The synthesis of new polymeric materials, B. The polymeric materials form hydrogels with unique properties: is self-healable and thus becomes injectable, and additionally is responsive to pH and temperature. C. The polymeric materials form a mixture suitable for targeted delivery of gemcitabine to pancreatic cancer in solid tissue form. The composition consists of the polymeric materials, water and gemcitabine, forming strong hydrogels and transfers gemcitabine selectively to local pancreatic cancer tissue. Two polymeric materials are presented. One is a pentablock tripolymer of poly(L-lysine) and poly(L-histidine-co-y-benzyl L-glutamate), while the other one is a hybrid tetrapolymer containing poly(ethylene oxide), poly(L-lysine) and poly(L-histidine-co-v-benzyl L-glutamate). The polymeric materials are injectable, in-situ forming and rapidly self-healing, they are not cytotoxic up to 400 mg/kg after in vivo studies in mice, according to the National Cancer Institute of USA. The composition responds to temperature and pH through a conversion from liquid to solid and a transformation of the secondary structure of the polymeric material. This multifunctionality allows the mixture to be placed near and in contact with the cancer tissue with the simplest possible application, i.e. via injection with a very thin needle. Furthermore, due to pH- and temperature-responsiveness, the mixtures melt and convert to liquids near the cancer tissue and thus are absorbed selectively by it, while they remain strong hydrogels at the healthy tissue, blocking release of the drug. In this way, the release of the drug is directed only to the cancer tissue. Our invention is unique and operates differently from other pH- and temperature-responsive hydrogel systems where the conversion from viscous liquid to hydrogel is effected in situ due to the lower pH and the higher temperature of the cancer tissues. Our composition is converted in situ from hydrogel to liquid due to conversion of the secondary structure, independently from the pH and temperature, and then melts selectively only towards the cancer tissue due to the lower pH and the higher temperature, delivering and releasing the drug in a targeted and time-controlled manner.
A system and method are disclosed for the collection and aggregation of genomic, medical, and other data of interest for individuals and populations that may be of interest for analysis, research, pharmaceutical development, medical treatment, and so forth. Contributors become members of a community upon creation of an account and providing of data or files. The data is received and processed, such as to analyze, structure, perform quality control, and curate the data. Value or shares in one or more community databases are computed and attributed to each contributing member. The data is controlled to avoid identification or personalization. Third parties interested in the database information may contribute value (e.g., pay) for access and use. Value flows back to the members and to a system administrative entity.
Chromosomal translocations involving the mixed-lineage leukemia (MLL) locus generate potent oncogenic fusion proteins (oncoproteins) that disrupt regulation of developmental gene expression. By profiling the oncoprotein-target sites of 36 broadly representative MLL-rearranged leukemia samples, including three samples that underwent a lymphoid-to-myeloid lineage-switching event in response to therapy, we find the genomic enrichment of the oncoprotein is highly variable between samples and subject to dynamic regulation. At high levels of expression, the oncoproteins preferentially activate either an acute lymphoblastic leukemia (ALL) program, enriched for pro-B-cell genes, or an acute myeloid leukemia (AML) program, enriched for hematopoietic-stem-cell genes. The fusion-partner-specific-binding patterns over these gene sets are highly correlated with the prevalence of each mutation in ALL versus AML. In lineage-switching samples the oncoprotein levels are reduced and the oncoproteins preferentially activate granulocyte-monocyte progenitor (GMP) genes. In a sample that lineage switched during treatment with the menin inhibitor revumenib, the oncoprotein and menin are reduced to undetectable levels, but ENL, a transcriptional cofactor of the oncoprotein, persists on numerous oncoprotein-target loci, including genes in the GMP-like lineage-switching program. We propose MLL oncoproteins promote lineage-switching events through dynamic chromatin binding at lineage-specific target genes, and may support resistance to menin inhibitors through similar changes in chromatin occupancy.
Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
Preoperative anxiety can compromise surgical outcome. Anxiety increases serum cortisol, adrenaline, and noradrenaline. This results in postoperative pain, increased postoperative analgesic requirements, prolonged hospital stay and patient dissatisfaction. However, this anxiety can be reduced.

Patient education has been widely used to reduce operative anxiety; however, some patients have more anxiety after patient education. This incident could be explained by different individual's coping styles that patients use to deal with their anxiety. There are four major coping style: vigilant, avoidant, fluctuating, and flexible. Vigilant coper desires extended information to reduce anxiety. Avoidant coper desires minimal amount of information as too much will cause anxiety. Fluctuating coper generally desires small amount of information but desires greater detail in certain area. Flexible coper is able to adapt to whatever information available. Thus, if patient education with extended information is given to patients with avoidant coping style, they will have more anxiety. One study found that avoidant coping style is 31% of surgical patients in the study population. This is also supported by another study that one-third of patients reported to be worried after receiving an informative booklet. Therefore, to be able to deal with all types of coping style, patient education with different levels of information regarding patient needs is proposed to be developed.

Needs-based patient education has become more promising with increased supporting literature. It uses the principle of shared decision making, which is the pinnacle of patient-centered care. Needs-based patient education is also consistent with adult learning theory, which learning should be matched with different individual background and needs. A randomized controlled trial was conducted to compare needs-based patient education with traditional patient education in rheumatoid arthritis and found a superior result. However, there is still lack of evidence in using needs-based patient education in surgery.

This study evaluates needs-based patient education in reducing preoperative anxiety. To assess patient needs, a questionnaire is used as a tool. After receiving completed questionnaire, the physician provides information based on patient needs. Not only patients will benefit from this questionnaire but also physicians. The questionnaire enables physician to cut unnecessary information and pay more attention to the fact that patients need. Less information needed is less time spent in patient education session. As the most important reason why patient education is omitted is shortness of time. This needs-based patient education can contribute tremendously to the way we educate surgical patients.

Objectives This study aims to compare needs-based patient education to traditional patient education in how they affect preoperative anxiety, patient satisfaction, and time consumption.
Ubiquitous pollution due to microplastics through the food chain is a major cause of various deleterious effects on the human health. The aim of this study was to determine the existence of microplastics and the internal mechanism of microplastics as accelerators of cholelithiasis. Gallstones were collected from 16 patients after cholecystectomy, and microplastics in the gallstones were detected through laser direct infrared and pyrolysis gas chromatographymass spectrometry examinations. Mice model of gallstone were constructed with or without different diameters of microplastic (0.5, 5 and 50 µm). The affinity between microplastic and cholesterol or bilirubin was tested by co-culturing and qualified using molecular dynamics simulations. Finally, altered gut microbiota among the groups were identified using 16 s rRNA sequencing. The presence of microplastics in the gallstones of all the patients were confirmed. Microplastic content was significantly higher in younger chololithiasis patients (age<50 years). Mice fed a high-cholesterol diet with microplastic drinks showed more severe chololithiasis. In terms of the mechanism, microplastics showed a higher affinity for cholesterol than for bilirubin. Significant alterations in the gut microbiota have also been identified after microplastic intake in mice. Our study revealed the presence of microplastics in human gallstones, showcasing their potential to aggravate chololithiasis by forming large cholesterol-microplastic heteroaggregates and altering the gut microbiota.
PURPOSE: A composition for treating atherosclerosis is provided to enable binding tissue through plural covalent bonds. CONSTITUTION: A composition for coating hallow organs or tissue contains polysaccharides with a functional group of chemical formula 1, 2, 3, or 4 as an active ingredient. The polysaccharides are alginic acid. The tissue is blood vessel or artery. The composition additionally contains therapeutically active material or contrast. A method for coating comprises: a step of preparing the composition; and a step of coating at least one part of the hollow organs or tissues with the composition.
PCT No. PCT/JP93/01603 Sec. 371 Date Jun. 15, 1995 Sec. 102(e) Date Jun. 15, 1995 PCT Filed Nov. 5, 1993 PCT Pub. No. WO94/10998 PCT Pub. Date May 26, 1994In producing a composition for solid medicine, comprising, as an active ingredient, a potassium channel activator and a pharmaceutically acceptable water-insoluble cellulose polymer, a method for producing a composition for solid medicine, which is characterized by dissolving a potassium channel activator in a solvent to give a medical solution, adding said medical solution to a water-insoluble cellulose polymer inert to said solvent in an amount necessary and sufficient to achieve a predetermined elution rate, homogeneously mixing them and drying the mixture to remove the solvent, and a composition for solid medicine, which is obtainable by said production method. According to the method of the present invention, elution rate of the active ingredient of a preparation comprising a potassium channel activator, which is a sustained release preparation, can be controlled with ease and with good reproducibility.
Provided herein are methods of treating an IDH mutant cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an all-trans retinoic acid (ATRA). In some embodiments, the methods increase an NK-cell-mediated immune response and/or a T cell-mediated immune response to the cancer. In some embodiments, the cancer is a glioma or a chondrosarcoma. In some embodiments, the expression of one or more NKG2D ligands (e.g., ULBP1 and ULBP3) is increased in a tumor microenvironment of the cancer. In some embodiments, CCL2 production, the number of NK cells, and/or apoptosis of tumor cells is increased in a tumor microenvironment of the cancer. In some embodiments, the subject has an IDH1 mutation at arginine 132 or an IDH2 mutation at arginine 172. In some embodiments, method reduces growth of a tumor.
Astragalus 60g. Oral administration, twice one day, for 12weeks.
Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL-CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL-CML. Tyrosine Kinase Inhibitors (TKI) prescription records collected from the ARIA regional registry were used to estimate the number of CML patients followed in smaller centers not participating in REL-CML. A total of 2285 patients were registered, representing a prevalence of 0.23 ‰. These data were compared to a similar census conducted in 2005, at the beginning of the TKI era, where a prevalence of 0.029‰ was calculated. This indicates that an almost 10 times increase took place during this period of time. Imatinib represents the most frequently prescribed first-line TKI; its use in 2022 still represented 75% of total first line prescriptions. An increased concentration of the care of CML patients in specialized REL centers with a decreased dispersion of patients in small centers was also evident over this 18 year period of time. Nineteen % of patients discontinued treatment, highlighting persisting logistical and biological challenges; one some recommendations on CML management are included to this aim.
Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, \& dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 15 mg of lenalidomide will be administered on daily on Days 1-21.
The application discloses rhabdovirus envelope protein, a targeting lentivirus vector containing the rhabdovirus envelope protein and application of the rhabdovirus envelope protein and the targeting lentivirus vector. The rhabdovirus envelope protein comprises an amino acid sequence shown as SEQ ID NO. 1 or 2. The envelope protein combination comprises the rhabdovirus envelope protein; and a targeting protein consisting of the following elements in sequence: transmembrane domain, linker sequence and single chain antibody. The recombinant lentiviral vector comprises the envelope protein combination. The recombinant lentiviral vector provided by the application effectively improves the transduction efficiency and specificity of human CD34+ hematopoietic stem cells, lays a foundation for future in vivo delivery, greatly reduces the treatment cost while increasing the safety, and has a great practical value.
The study was conducted for the purpose of determining the effect of making children aged 5 to 12 years watch a cartoon about echocardiography (ECO) procedure before the procedure and kaleidoscope during the procedure on their anxiety. It is a randomized controlled study. The study was conducted in the Pediatric Cardiology Polyclinic of Afyon Kocatepe University Ahmet Necdet Sezer Research and Application Hospital in the Province of Afyonkarahisar between 6 November 2018-1 February 2019. The study was completed with a total of 164 children who came to have an ECO and met the sample selection criteria. There were four groups in the study which were as follows; the group that was made watch a cartoon about the procedure before the procedure, the group that was made watch a kaleidoscope during the procedure, the group that was made watch a cartoon about the procedure before the procedure and a kaleidoscope during the procedure and the control group in which routine applications of clinic were carried out. Samples were assigned to the groups using permutation block randomization method. In order to collect data, an Introductory Information Form and the Child Fear Scale were used. The data acquired from the study were evaluated using the IBM SPSS Statistics 24 (Statistical Package for Social Sciences) package software. In our study, the experimental and control group children were found to be similar in terms of introductory characteristics (age, gender, educational level, family structure, number of children in family, illness and hospital experiences, information about ECO). At the end of the study, it was determined that anxiety scores of the cartoon group, cartoon+kaleidoscope group and the kaleidoscope group were lower during the procedure than before the procedure (p\<0,001). In the control group, it was determined that there was no significant difference between the anxiety scores before and during the procedure (p\>0,05).
Persons with HIV (PWH) experience high levels of pain. We examined the relationship of pain severity with use of cannabis and prescription opioids among PWH. This cross-sectional study evaluated associations between self-reported pain (moderate/severe vs mild/none) and cannabis and prescription opioid use in a primary care sample of PWH enrolled in an alcohol use treatment study at Kaiser Permanente, San Francisco. Prevalence ratios (PR) for moderate/severe pain associated with cannabis, opioid use, or both in the prior 30 days were obtained from Poisson regression models. Adjusted models included race/ethnicity, education, employment, HIV ribonucleic acid levels, depression, and anxiety. Overall, 614 PWH completed baseline questionnaires from May 2013 to May 2015, among whom 182/614 (29.6%) reported moderate/severe pain. The prevalence of moderate/severe pain varied by substances: 19.1% moderate/severe pain among study participants who reported neither cannabis or opioids, 30.2% for cannabis alone, 41.2% for opioids alone, and 60.9% for those reporting both substances. In adjusted models, compared with PWH who reported neither substance (reference), prevalence of moderate/severe pain was higher for those using cannabis alone (PR 1.54; 95% CI 1.13-2.09), opioids alone (PR 1.96; 95% CI 1.31-2.94), and those reporting both (PR 2.66; 95% CI 1.91-3.70). PWH who reported opioid and/or cannabis use were more likely to report moderate/severe pain compared with PWH who did not report use of these substances. To improve patient care, it is vital to assess patients' approaches to pain management including substance use and target appropriate interventions to reduce pain in PWH.